CMBA
CLSD

C.M. Bidwell & Associates’s Clearside Biomedical CLSD Stock Holding History

C.M. Bidwell & Associates’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-78
Closed -$3K – 501
2022
Q1 		$3K Buy
+78
New +$2.33K ﹤0.01% 436

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

C.M. Bidwell & Associates's CLSD Position: Q2 2022 in Review

C.M. Bidwell & Associates sold out of Clearside Biomedical (CLSD) in Q2 2022, closing a stake of 78 shares — an estimated $3K sold.

C.M. Bidwell & Associates first reported a position in CLSD in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 53 funds tracked by Wall St. Rank hold CLSD as of Q2 2022.

  • C.M. Bidwell & Associates reported no remaining Clearside Biomedical position as of Q2 2022 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 78 Clearside Biomedical shares in Q2 2022, an estimated $3K.
  • C.M. Bidwell & Associates first reported a position in Clearside Biomedical in Q1 2022 and held it in 1 quarter.
  • C.M. Bidwell & Associates's Clearside Biomedical position peaked at $3K in Q1 2022.
  • 53 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2022.

Based on C.M. Bidwell & Associates's 13F filing for Q2 2022, filed 12 Aug 2022.